CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported revenue of $1.00B for the period ended 2026-06-27, -2.7% year on year. Net income was $-0.00B, a -0.1% net margin on a 100.0% gross margin. The largest revenue line is Discovery And Safety Assessment at 60% of the total. Free cash flow for the period was $0.15B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | $1.00B | -2.7% |
| Gross profit | $1.00B | — |
| Operating income | $0.12B | — |
| Net income | $-0.00B | -102.8% |
| Gross margin | 100.0% | Net margin -0.1% |
| Revenue Q/Q | +0.8% | — |
| Segment | Revenue | Share |
|---|---|---|
| Discovery And Safety Assessment | $0.61B | 60.4% |
| Research Models And Services | $0.21B | 20.9% |
| Manufacturing Support | $0.19B | 18.7% |
| Item | Amount | % of revenue |
|---|---|---|
| SG&A | $0.23B | 22.8% |
| Tax & other | $0.12B | 12.1% |
| Item | Amount |
|---|---|
| Total assets | $7.53B |
| Total liabilities | $4.64B |
| Shareholders' equity | $2.89B |
| Equity / assets | 38.3% |
| Operating cash flow | $0.18B |
| Capital expenditure | $0.03B |
| Free cash flow | $0.15B |
| Cash conversion (OCF / net income) | -12127% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
SCHW ・ CHTR ・ CVX ・ CMG ・ CB ・ CHD ・ CIEN ・ CI ・ CINF ・ CTAS ・ CSCO ・ C
Source: SEC EDGAR · This page shows public filing data only, not investment advice. · Browse all companies